Low-Dose Cyproterone Acetate Treatment for Transgender Women
Abstract
Transgender women with intact gonads receive lifelong hormonal treatment to suppress physiologic androgen production, the optimal efficacious and safe cyproterone acetate (CPA) dose has not been established.To assess the effectiveness and safety of low-dose (10-20 mg/day) compared with high-dose (50-100 mg/day) CPA treatment.We conducted a historical cohort study of transgender women treated at a tertiary center for transgender health.Serum...
Paper Details
Title
Low-Dose Cyproterone Acetate Treatment for Transgender Women
Published Date
Jun 24, 2021
Volume
18
Issue
7
Pages
1292 - 1298
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History